| WO1996006620A2 (en) | 1994-08-29 | 1996-03-07 | Wake Forest University | Lipid analogs for treating viral infections |
| US7135584B2 (en)* | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US7303768B2 (en) | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US20070072828A1 (en)* | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US7772220B2 (en)* | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20050158408A1 (en)* | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7026469B2 (en)* | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| WO2001056547A2 (en)* | 2000-02-04 | 2001-08-09 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| KR100905221B1 (en) | 2000-10-18 | 2009-07-01 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| WO2002044717A1 (en)* | 2000-12-01 | 2002-06-06 | Cornell Research Foundation | Animal model for flaviviridae infection |
| WO2002048165A2 (en)* | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| WO2002096826A2 (en)* | 2001-05-29 | 2002-12-05 | Koninklijke Philips Electronics N.V. | Metal-ceramic bond |
| US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| WO2003021959A1 (en)* | 2001-08-31 | 2003-03-13 | Thomson Licensing Sa | Sequence counter for an audio visual stream |
| US7138376B2 (en)* | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| JP2005522443A (en)* | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | Modified fluorinated nucleoside analogues |
| MXPA04009672A (en)* | 2002-04-01 | 2004-11-12 | Pfizer | Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase. |
| DOP2003000641A (en)* | 2002-05-10 | 2003-11-15 | Pfizer | INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUSES AND COMPOSITIONS AND TREATMENT USED |
| CN104193791A (en) | 2002-06-28 | 2014-12-10 | 埃迪尼克斯医药公司 | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections |
| AU2003257157C1 (en)* | 2002-08-01 | 2010-03-18 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1] nonane system for the treatment of Flaviviridae infections |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| US7148226B2 (en)* | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| US20040214178A1 (en)* | 2003-04-24 | 2004-10-28 | Agouron Pharmaceuticals, Inc. | Reporter-selectable Hepatitis C virus replicon |
| EP1633766B1 (en) | 2003-05-30 | 2019-03-06 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| WO2005009418A2 (en) | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| US20050187191A1 (en)* | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
| US20050187192A1 (en)* | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
| ES2361845T3 (en)* | 2004-08-18 | 2011-06-22 | Pfizer, Inc. | RNA POLYMERASE INHIBITORS DEPENDING ON HEPATITIS C VIRUS RNA AND COMPOSITIONS AND TREATMENTS USING THE SAME. |
| JP2008511651A (en)* | 2004-08-30 | 2008-04-17 | セオ ホン ユー | Neuroprotective effect of solubilized UDCA in a local ischemia model |
| MX2007003085A (en) | 2004-09-14 | 2007-08-02 | Pharmasset Inc | Preparation of 2' ifluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives. |
| CN101056656A (en)* | 2004-09-15 | 2007-10-17 | 哈佛大学校长及研究员协会 | Reducing ER stress in the treatment of obesity and diabetes |
| US7196161B2 (en)* | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| ATE530561T1 (en)* | 2004-10-01 | 2011-11-15 | Scynexis Inc | 3-ETHER AND 3-THIOETHER SUBSTITUTED CICLOSPORINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION |
| KR20070084211A (en)* | 2004-10-15 | 2007-08-24 | 유서홍 | Methods and Compositions for Reducing Toxicity of Pharmaceutical Compounds |
| JP2008518935A (en)* | 2004-11-01 | 2008-06-05 | セオ ホン ユー | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| RU2294207C2 (en)* | 2005-04-18 | 2007-02-27 | Учебно-научный центр Медицинского центра Управления делами Президента РФ | Method for treatment of diseases caused and accompanying disturbance in metabolism of bile acids and cholesterol |
| CA2623865A1 (en)* | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
| CA2679608A1 (en)* | 2006-03-22 | 2007-10-04 | President And Fellows Of Harvard College | Methods and compositions for treating hypercholesterolemia and atherosclerosis |
| RU2448976C2 (en) | 2006-04-11 | 2012-04-27 | Новартис Аг | Hcv/hiv inhibitors and their application |
| US8188052B2 (en) | 2006-05-19 | 2012-05-29 | Scynexis, Inc. | Method for the treatment and prevention of ocular disorders |
| JP2009539292A (en)* | 2006-06-02 | 2009-11-12 | ぺリション、クロード、アニー | Management of active electrons |
| US7576057B2 (en) | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
| AU2008219622A1 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2197439A2 (en)* | 2007-10-10 | 2010-06-23 | Hanall Pharmaceutical Co., Ltd. | Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid |
| TW200946541A (en)* | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US20100003217A1 (en) | 2008-07-02 | 2010-01-07 | Erika Cretton-Scott | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections |
| EP3222628A1 (en) | 2008-12-23 | 2017-09-27 | Gilead Pharmasset LLC | Nucleoside phosphoramidates |
| CA2748034A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections |
| CN102325783A (en) | 2008-12-23 | 2012-01-18 | 法莫赛特股份有限公司 | Synthesis of purine nucleosides |
| US8536114B2 (en)* | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (en) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| AR079528A1 (en) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | 5,5-FUSIONED ARYLENE OR HETEROARYLENE INHIBITORS OF HEPATITIS C VIRUS |
| PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
| WO2011123645A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| CN102917585A (en) | 2010-04-01 | 2013-02-06 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EA201390532A1 (en) | 2010-10-08 | 2013-09-30 | Новартис Аг | COMPOSITIONS OF NS3 SULFAMIDE INHIBITORS CONTAINING VITAMIN E |
| TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
| WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
| MD4177C1 (en)* | 2011-01-14 | 2013-02-28 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Method for vaccination against hepatitis B of persons with immunodeficiency |
| TW201309690A (en) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| WO2012107584A1 (en) | 2011-02-11 | 2012-08-16 | Universite Pierre Et Marie Curie (Paris 6) | Methods for predicting outcome of a hepatitis virus infection |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2739301B1 (en) | 2011-08-03 | 2016-01-20 | Cytheris | Hcv immunotherapy |
| CN103906759A (en) | 2011-09-12 | 2014-07-02 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (en) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
| AR089650A1 (en) | 2011-10-14 | 2014-09-10 | Idenix Pharmaceuticals Inc | PHOSPHATES 3,5-REPLACED CYCLES OF PURINE NUCLEOTIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN104185420B (en) | 2011-11-30 | 2017-06-09 | 埃默里大学 | Antiviral JAK inhibitor for treating or preventing retrovirus and other virus infection |
| US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
| KR20150013825A (en) | 2012-05-22 | 2015-02-05 | 아이데닉스 파마슈티칼스, 인코포레이티드 | D-amino acid compounds for liver disease |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| PE20151318A1 (en) | 2012-10-08 | 2015-10-03 | Idenix Pharmaceuticals Inc | 2'-NUCLEOSIDE CHLORINE ANALOGS FOR HCV INFECTION |
| MD596Z (en)* | 2012-10-09 | 2013-09-30 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Method for treating chronic viral hepatitis C in children |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
| WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| PT3650014T (en) | 2013-08-27 | 2021-12-27 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| EP3063165A1 (en) | 2013-11-01 | 2016-09-07 | Idenix Pharmaceuticals LLC | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
| EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| JP7376871B2 (en)* | 2019-09-18 | 2023-11-09 | 救心製薬株式会社 | Medical uses of Senso and Goou |